Zusammenfassung
Tierstudien und vor allem auch NASCIS II haben die neuroprotektive Wirkung des Methylprednisolons mit hoher Sicherheit belegt, sie sind jedoch nicht unumstritten. An der Universitätsklinik für Unfallchirurgie, Wien, erhielten vom 13. 4. 1991 bis 30. 11 1993 31 Patienten mit Wirbelsäulentrauma und Querschnittssymptomatik Methylprednisolon in Megadosis mit einem Bolus von 30 mg/kg Körpergewicht, gefolgt von einer Erhaltungsdosis von 5,4 mg/kg KG/h für 23 Studen. Bei 27 dieser Patienten wurde innerhalb von acht Stunden die primäre operative Reposition und Stabilisierung durchgeführt. Der Nachuntersuchungszeitraum lag zwischen ein bis 3,2 Jahren. Es fand sich bei allen Patienten (100%) mit inkompletter Querschnittssymptomatik (n=18) eine deutliche Besserung und immerhin bei drei Patienten (23.1%) mit komplettem Querschnitt (n=13). Im Vergleich dazu überblicken wir 113 Patienten mit kompletter oder inkompletter Querschnittssymptomatik, die in den Jahren 1980 bis 1990 an der ehemaligen I. Universitätsklinik für Unfallchirurgie aufgenommen wurden und nach unseren derzeitigen Kriterien Methylprednisolon hätten erhalten sollen.
Abstract
Studies in animals and especially the NASCIS II study illustrated the neuroprotective effects of methylprednisolone, but they are disputed. At the University Clinic of Traumatology, Vienna, 31 patients with spinal cord injuries were given methylprednisolone as a bolus of 30 mg/kg body weight followed by a maintenance dose of 5.4 mg/kg body weight/h for another 24 hours. Twenty-seven patients were stabilised within 8 hour, 2 patients were not operated on, because of their low prognosis. Two patients could be treated conservatively, because the spinal fractures were supposed to be stabile. Then follow-up studies of these patients were between 1 and 3,2 years. All patients (100%) with incomplete neurologic deficits (n=18) showed a significant recovery and even 3 patients (23.1%) with primarily a complete tetraplegia (n=13) showed a nearly entire recovery. Compared to these results we look back at 113 patients with complete and incomplete neurologic deficits who were treated at the I. University Clinic of Traumatology, Vienna, and would have got methylprednisolone following our current management procedures.
Literatur
Anderson, D. K., E. D. Means, D. R. Waters et al.: Microvascular perfusion and metabolism in injured spinal cord after methylprednisolone treatment. J. Neurosurg. 56 (1982), 106–113.
Antal, E. J., E. Wright, W. R. Gillespie, K. S. Albert: Influence of route of administration on the pharmacokinetics of methylprednisolone. J. Pharmacokinet. Pharmaceut. 11 (1983), 561–576.
Bracken, M. B., W. F. Collins, D. F. Freeman et al.: Efficacy of methylprednisolone in acute spinal cord injury. J. Amer. med. Ass. 251 (1984), 45–52.
Bracken, M. B., M. J. Shepard, W. F. Collins et al.: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. New Engl. J. Med. 322 (1990), 1405–1411.
Bracken, M. B., M. J. Shepard, W. F. Collins et al.: Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. J. Neurosurg. 76 (1992), 23–31.
Bracken, M. B.: Pharmacological treatment of acute spinal cord injury: current status and future prospects. Paraplegia 30 (1992), 102–107.
Braughler, J. M., E. D. Hall: Uptake and elimination of methyl-prednisolone from contused cat spinal cord following intravenous injection of the sodium succinate ester. J. Neurosurg. 58 (1983), 538–542.
Braughler, J. M., E. D. Hall: Effects of multi-dose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J. Neurosurg. 61 (1984), 290–295.
Braughler, J. M., E. D. Hall: Current application of “high-dose” steroid therapy for CNS injury. J. Neurosurg. 62 (1985), 806–810.
Braughler, J. M., E. D. Hall, J. M. McCall, J. M. Means: The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia, Drugs Future 14 (1989), 143–152.
Demopoulos, H. B., E. S. Flamm, D. D. Pietronigro et al.: The free radical pathology and the microcirculation in the major central nervous disorders. Acta physiol. scand. 492, Suppl. 111 (1980), 1–119.
Demopoulos, H. B., E. S. Flamm, M. L. Seligman et al.: Further studies on free-radical pathology in the major central nervous disorders: effects of very high doses of methylprednisolone on the functional outcome, morphology, and chemitry of experimental spinal cord impact injury. Canad. J. Physiol. Pharmacol. 60 (1982), 1415–1424.
Emerson, T. E., W. J. Bryon: Regional cerebral blood flows in endotoxin shock with methylprednisolone treatment. Proc. Soc. exp. Biol. Med. 156 (1977), 378–381.
Fox, J. L., M. G. Yargasil: The relief of intracranial vasospasm: an experimental study with methylprednisolone and cortisol. Surg. Neurol. 3 (1975), 214–218.
Geisler, F. H., F. C. Dorsey, W. P. Coleman: Recovery of motor function after spinal-cord injury—a randomized placebo controlled trial with GM-1 ganglioside. New Engl. J. Med. 26 (1991), 1829–1837.
Gianotta, S. L., M. H. Weiss, M. L. J. Apuzzo et al.: High dose glucocorticoids in the management of severe head injury. Neurosurgery 15 (1984), 497–501.
Hall, E. D., T. Baker: Acute effects of methylprednisolone sodium succinate on spinal reflexes. Exp. Neurol. 63 (1979), 476–484.
Hall, E. D. et al: Further studies of glucocorticoid effects on spinal cord function: single and repetitive monosynpatic transmission and apparent Ia afferent transmitter turnover. J. Pharmacol. exp. Ther. 210 (1979), 112–115.
Hall, E. D., D. L. Wolf, J. M. Braughler: Effects of a single large dose of methylprednisolone sodium succinate on experimental posttraumatic spinal cord ischemia. Dose-response and time-action analysis. J. Neurosurg. 61 (1984), 124–130.
Hall, E. D., D. L. Wolf: A pharmacological analysis of the pathophysiological mechanisms of posttraumatic spinal cord ischemia. J. Neurosurg. 64 (1986), 951–961.
Hall, E. D.: The neuroprotective pharmacology of methylprednisolone. J. Neurosurg. 76 (1992) 13–22.
Hanigan, W. C., R. J. Anderson: Commentary on NASCIS-2. J. spinal Disord. 5 (1992), 125–131.
Hilton, G., J. Frei: High-dose methylprednisolone in the treatment of spinal cord injuries. Heart and Lung 20 (1991), 675–680.
Melo-Gomes, J. A.: Problems related to systemic glucocorticoid therapy in children. J. Rheum. 20 Suppl. 37 (1993), 35–39.
Möllmann, H., P. Rohdewald, J. Barth et al.: Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. Pharmaceut. Res. 5 (1988), 509–513.
Schnell, L., M. E. Schwab: Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 343 (1990), 269–272.
Schwab, M. E.: Entwicklung, Stabilisierung und Regeneration von Faserverbindungen in Gehirn und Rückenmark: Die Rolle von Nervenwachstumschemmstoffen. In: Zäch, G. A., Rehabilitation beginnt am Unfallort. Springer, Berlin-Heidelberg-New York 1992.
Soejima, T., Y. L. Yamamoto, E. Meyer et al.: Protective effects of steroids on the cortico-microcirculation injured by cold. J. Neurosurg. 51 (1979), 188–200.
Woodbury, D., W. G. Bingham: Effects of steroids on the central nervous system. In: Dorfman, R. I.: Steroidal activity in experimental animals an man. Part C. Methods in hormone research. Academic Press, New York-London 1966.
Young, W.: Therapy of acute spinal cord injury. 7th Congress of the Western Pacific Association of Critical Care Medicine, 12–15th March 1993, Hongkong 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gäbler, C., Maier, R. Klinische Erfahrungen und Ergebnisse der hochdosierten Methylprednisolontherapie bei Rückenmarkstrauma von 1991 bis 1993. Unfallchirurgie 21, 20–29 (1995). https://doi.org/10.1007/BF02588347
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02588347